Study #2020-0158
Diet and Immune Effects Trial: DIET- A randomized double blinded dietary intervention study in patients with metastatic melanoma receiving immunotherapy
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
This phase II trial investigates the possible immune effects of two different diets targeting the gut microbiome in patients with stage III-IV melanoma that has been removed by surgery (resectable), has spread to other places in the body (metastatic), or is unable to be removed by surgery (unresectable), and who are being treated with the immunotherapy drugs pembrolizumab or nivolumab as part of their standard of care. Both diets are whole foods diets that meet the American Cancer Society recommendations for cancer patients, but they will vary in fiber content. The purpose of this trial is to learn about the effects of dietary interventions on the structure and function of the gut microbiome in patients with melanoma being treated with standard of care immunotherapy (pembrolizumab or nivolumab).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Clinical Stage III Cutaneous Melanoma AJCC v8;Clinical Stage IV Cutaneous Melanoma AJCC v8;Metastatic Melanoma;Pathologic Stage III Cutaneous Melanoma AJCC v8;Pathologic Stage IV Cutaneous Melanoma AJCC v8;Unresectable Melanoma
Study phase:
Phase II
Physician name:
Jennifer McQuade
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.